Wesolow Jacqueline T, Jalali Samuel, Clark Leah D
Internal Medicine, Moffitt Cancer Center, Tampa, USA.
Oncology, Moffitt Cancer Center, Tampa, USA.
Cureus. 2021 Jul 4;13(7):e16169. doi: 10.7759/cureus.16169. eCollection 2021 Jul.
Bullous pemphigoid is a serious and rare complication of immunotherapy. Here, we present a case of bullous pemphigoid secondary to ipilimumab/nivolumab checkpoint inhibitor therapy in a patient with metastatic melanoma. Immune checkpoint inhibitor therapy is more widely used now to treat cancer patients, bringing more challenging cases of adverse events associated with their use. Bullous pemphigoid can be a difficult diagnosis to make in the initial stages as the rash is similar to other red rashes before transforming into the typical appearance of a blister. As bullous pemphigoid can be a life-threatening adverse event, early identification is key to increasing patient survival.
大疱性类天疱疮是免疫治疗一种严重且罕见的并发症。在此，我们报告一例继发于伊匹单抗/纳武单抗检查点抑制剂治疗的转移性黑色素瘤患者发生大疱性类天疱疮的病例。免疫检查点抑制剂疗法目前在癌症患者治疗中应用更为广泛，也带来了更多与之相关的具有挑战性的不良事件病例。大疱性类天疱疮在初始阶段可能难以诊断，因为皮疹在转变为典型的水疱外观之前与其他红色皮疹相似。由于大疱性类天疱疮可能是危及生命的不良事件，早期识别是提高患者生存率的关键。
